1. Home
  2. ENTA vs VWAV Comparison

ENTA vs VWAV Comparison

Compare ENTA & VWAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • VWAV
  • Stock Information
  • Founded
  • ENTA 1995
  • VWAV 2024
  • Country
  • ENTA United States
  • VWAV United States
  • Employees
  • ENTA N/A
  • VWAV N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • VWAV Computer Software: Prepackaged Software
  • Sector
  • ENTA Health Care
  • VWAV Technology
  • Exchange
  • ENTA Nasdaq
  • VWAV Nasdaq
  • Market Cap
  • ENTA 164.6M
  • VWAV 162.2M
  • IPO Year
  • ENTA 2013
  • VWAV N/A
  • Fundamental
  • Price
  • ENTA $10.96
  • VWAV $13.27
  • Analyst Decision
  • ENTA Strong Buy
  • VWAV
  • Analyst Count
  • ENTA 5
  • VWAV 0
  • Target Price
  • ENTA $21.00
  • VWAV N/A
  • AVG Volume (30 Days)
  • ENTA 518.3K
  • VWAV 372.5K
  • Earning Date
  • ENTA 11-17-2025
  • VWAV 11-26-2025
  • Dividend Yield
  • ENTA N/A
  • VWAV N/A
  • EPS Growth
  • ENTA N/A
  • VWAV N/A
  • EPS
  • ENTA N/A
  • VWAV N/A
  • Revenue
  • ENTA $64,806,000.00
  • VWAV N/A
  • Revenue This Year
  • ENTA $0.07
  • VWAV N/A
  • Revenue Next Year
  • ENTA N/A
  • VWAV N/A
  • P/E Ratio
  • ENTA N/A
  • VWAV N/A
  • Revenue Growth
  • ENTA N/A
  • VWAV N/A
  • 52 Week Low
  • ENTA $4.09
  • VWAV $2.06
  • 52 Week High
  • ENTA $15.34
  • VWAV $14.05
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 54.87
  • VWAV N/A
  • Support Level
  • ENTA $10.30
  • VWAV N/A
  • Resistance Level
  • ENTA $11.45
  • VWAV N/A
  • Average True Range (ATR)
  • ENTA 0.62
  • VWAV 0.00
  • MACD
  • ENTA -0.12
  • VWAV 0.00
  • Stochastic Oscillator
  • ENTA 41.67
  • VWAV 0.00

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About VWAV VisionWave Holdings Inc. Common Stock

VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.

Share on Social Networks: